Channelpedia

PubMed 19682955


Referenced in Channelpedia wiki pages of: none

Automatically associated channels: Kv1.1



Title: Anticonvulsant effects of the selective melatonin receptor agonist ramelteon.

Authors: Kristina Fenoglio-Simeone, Andréy Mazarati, Sepideh Sefidvash-Hockley, Don Shin, Julianne Wilke, Heather Milligan, Raman Sankar, Jong M Rho, Rama Maganti

Journal, date & volume: Epilepsy Behav, 2009 Sep , 16, 52-7

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/19682955


Abstract
The endogenous hormone melatonin has previously been shown to exert anticonvulsant effects in a variety of experimental models. Accordingly, we asked whether ramelteon, a synthetic and selective melatonin receptor agonist, might also possess anticonvulsant and/or antiepileptogenic properties.The effects of ramelteon (30 or 100 mg/kg intraperitoneally twice daily for 5 days) were evaluated in two animal models of epilepsy. In the rat rapid kindling model, baseline hippocampal afterdischarge properties, kindling progression, and hippocampal excitability in kindled animals were measured. Anti-ictogenic efficacy was assessed after acute administration in untreated kindled rats. In the spontaneously epileptic Kcna1-null mouse model, we determined seizure frequency and periodicity using continuous video/EEG monitoring over 72 hours. Further, circadian rest-activity rhythms in ramelteon-treated animals were studied with actigraphy.In kindled animals, ramelteon reversed kindling-induced hippocampal excitability; however, it did not modify baseline afterdischarge properties, the progression and establishment of the kindled state in the rapid kindling model. However, in Kcna1-null mice, ramelteon (200 mg/kg/day) significantly attenuated seizure periodicity and frequency and improved circadian rest-activity rhythms compared with control animals.The selective melatonin receptor agonist ramelteon possesses anticonvulsant properties in a chronic epilepsy model. Our findings provide further support for melatonin receptors being potential novel targets for anticonvulsant drug development.